Management of Subtherapeutic INR After Missed Warfarin Doses
Resume the patient's usual warfarin maintenance regimen (5 mg Monday-Friday, 2.5 mg Saturday-Sunday) immediately and recheck the INR within 1-2 weeks without making any dose adjustments.
Rationale for Continuing Current Dose
The American College of Chest Physicians (ACCP) guidelines explicitly address this scenario. For patients with previously stable therapeutic INRs who present with a single out-of-range INR of 0.5 below therapeutic range, the recommendation is to continue the current dose and test the INR within 1-2 weeks 1.
Your patient's INR of 1.8 falls within the range where dose changes are not indicated. The guidelines note that an observational study of 3,961 patients demonstrated that warfarin doses did not need to be changed for INRs between 1.7 and 3.3 1, 2. In fact, research shows that optimal warfarin management involves changing doses only when INR drops to 1.7 or lower, or rises to 3.3 or higher 2.
Why Not to Adjust the Dose
An open-label randomized controlled trial compared one-time dose increases versus continuing the same dose when INR was slightly below therapeutic range (1.5-4.4). Results showed no significant difference at 2-week follow-up: 44% remained outside therapeutic range with dose changes versus 40% without dose changes (OR 1.17,95% CI 0.59-2.30, P=0.75) 1. Making reactive dose adjustments to single out-of-range INRs does not improve outcomes.
Why Not to Use Loading Doses
The FDA label for Coumadin explicitly states: "Routine use of loading doses is not recommended as this practice may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation" 3. Loading doses are associated with increased bleeding risk without meaningful benefit in this context 4, 5.
Managing the Missed Doses
According to the FDA label, when a patient misses doses, they should resume taking warfarin as soon as possible and not double the dose to make up for missed doses 3. The anticoagulant effect of warfarin persists beyond 24 hours, so the patient retains some anticoagulant effect even after missing two doses 3.
No Need for Bridging Therapy
The ACCP guidelines recommend against routinely administering bridging with heparin for patients with stable therapeutic INRs presenting with a single subtherapeutic INR value (Grade 2C) 1. Retrospective studies of 2,597 patients showed no significant difference in thromboembolic events between low-INR and therapeutic-INR cohorts 1.
Follow-Up Plan
- Recheck INR in 1-2 weeks to exclude progressive deviation from therapeutic range 1
- Resume more frequent INR monitoring (weekly) until a consistent pattern of stable therapeutic INRs is reestablished 1
- Once stable, can return to monitoring intervals of 1-4 weeks 3
Important Caveats
This recommendation assumes:
- The patient was previously stable on this regimen
- No new medications or significant dietary changes have occurred
- The patient's underlying indication for anticoagulation hasn't changed
- The patient is not at extremely high thrombotic risk (e.g., certain mechanical heart valves in mitral position)
If the patient has a mechanical heart valve or other very high-risk condition, consider consulting with cardiology or hematology, though even in these populations, bridging showed minimal benefit (thromboembolic event rate 0.3-0.4%) 1.